Latest News on QSI

Financial News Based On Company


Advertisement
Advertisement

QSI: Quantum-Si Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

https://quantisnow.com/insight/quantum-si-incorporated-filed-sec-form-8-k-regulation-fd-disclosure-financial-6798128
Quantum-Si Incorporated announced via an SEC Form 8-K filing that its Proteus development program successfully detected all 20 naturally occurring amino acids, achieving its year-end 2026 goal ahead of schedule. This milestone is expected to lay the groundwork for future reference-free protein identification, though commercial value remains unproven. The company noted it faces competitors with greater financial and marketing resources.

Weekly Recap: Revenue down, guidance held and Proteus delivers 30x output

https://www.tradingview.com/news/tradingview:112c80178d284:0-weekly-recap-revenue-down-guidance-held-and-proteus-delivers-30x-output/
Quantum-Si Incorporated (NASDAQ:QSI) reported a third-quarter revenue of $212,000, which is a decrease year-over-year, and a net loss of $22.3 million. Despite this, the company maintained its 2026 revenue guidance and anticipates having sufficient cash to fund operations until late 2028. Additionally, preliminary results for its Proteus system showed a 30-fold increase in sequencing output per chamber and a reduced false discovery rate compared to Platinum Pro in a peptide study.

After cutting about 20% of staff, Quantum-Si (QSI) lowers its 2026 spending forecast.

https://www.stocktitan.net/sec-filings/QSI/8-k-quantum-si-inc-reports-material-event-d064f9a8167c.html
Quantum-Si reported a Q3 2026 revenue of $212,000, down from the previous year, as it transitions from its Platinum to the anticipated Proteus platform, expected for commercial launch in Q2 2027. The company narrowed its net loss and adjusted EBITDA loss, and following a 20% staff reduction, it lowered its full-year 2026 guidance for operating expenses and cash usage, anticipating $12 million in annual savings. Quantum-Si expects its current cash and investments to fund operations into Q4 2028.

Technical Analysis of Quantum-Si Incorporated (NASDAQ:QSI)

https://www.tradingview.com/symbols/NASDAQ-QSI/technicals/
This article provides a technical analysis of Quantum-Si Incorporated (NASDAQ:QSI) based on various indicators like oscillators and moving averages. As of the analysis, the overall technical rating for QSI is neutral. It also includes frequently asked questions about technical ratings, pivots, and other indicators to help users understand the analysis.

Weekly Recap: NASDAQ:QSI regains bid compliance and Q3 2026 results call

https://www.tradingview.com/news/tradingview:530dcc7095641:0-weekly-recap-nasdaq-qsi-regains-bid-compliance-and-q3-2026-results-call/
Quantum-Si Incorporated Class A (NASDAQ:QSI) has regained Nasdaq minimum bid compliance after its stock maintained a price of $1.00 or above for ten consecutive trading days. The company is also scheduled to report its Q3 2026 financial results on November 5, 2026, which will be followed by a conference call and webcast at 4:30 PM ET. This update confirms QSI's continued listing compliance and upcoming earnings announcement.
Advertisement

Quantum-Si Regains Nasdaq Compliance After Bid Price Recovery

https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/8098656/quantum-si-regains-nasdaq-compliance-after-bid-price-recovery/
Quantum-Si (QSI) has announced that it has regained compliance with Nasdaq's minimum bid price requirement. The company had previously received a delisting notice on July 23, 2026, after its stock closed below $1.00 for 30 consecutive business days. As of October 13, 2026, Nasdaq confirmed that Quantum-Si's bid price had been at or above $1.00 for at least 10 consecutive business days, resolving the immediate delisting threat.

Quantum-Si Regains Nasdaq Compliance After Bid Price Recovery

https://www.theglobeandmail.com/investing/markets/stocks/QSI/pressreleases/8098656/quantum-si-regains-nasdaq-compliance-after-bid-price-recovery/
Quantum-Si (QSI) has successfully regained compliance with Nasdaq's minimum bid price requirement after its Class A common stock closed above $1.00 for at least 10 consecutive business days. The company had previously faced a delisting threat since July 23, 2026, when its stock fell below $1.00 for 30 consecutive days. While the immediate delisting risk is resolved, continued share-price weakness could jeopardize its Nasdaq listing again.

Quantum-Si Incorporated to Report Third Quarter 2026 Financial Results and Provide Business Update on November 5

https://www.moomoo.com/news/post/1001485182/quantum-si-incorporated-to-report-third-quarter-2026-financial-results
Quantum-Si Incorporated (QSI) will release its third quarter 2026 financial results and provide a business update on November 5, 2026. The company will host a conference call and webcast to discuss these results, which will be accessible via its investor relations website.

Closing bids of $1 or more bring a Nasdaq compliance decision for Quantum-Si (Nasdaq: QSI).

https://www.stocktitan.net/sec-filings/QSI/8-k-quantum-si-inc-reports-material-event-6af763bb4a12.html
Quantum-Si Incorporated (QSI) has regained compliance with Nasdaq's minimum bid price requirement. The company received notice on October 14, 2026, that its Class A common stock had maintained a closing bid price of $1.00 or more for at least 10 consecutive business days, resolving the prior non-compliance issue from July 23, 2026. QSI will continue to monitor its stock price to maintain compliance.

Quantum-Si Regains Nasdaq Minimum Bid Price Compliance, Delisting Matter Closed

https://www.minichart.com.sg/2026/10/15/quantum-si-regains-nasdaq-minimum-bid-price-compliance-delisting-matter-closed/
Quantum-Si Inc. announced that it has regained compliance with Nasdaq's minimum bid price requirement, closing the delisting matter. The company's Class A common stock has traded at or above $1.00 per share for at least 10 consecutive business days. Although the immediate threat of delisting is removed, Quantum-Si will continue to monitor its stock price as future non-compliance could lead to new delisting notices.
Advertisement

Quantum-Si (NasdaqGM:QSI) Stock Forecast & Analyst Predictions

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qsi/quantum-si/future
Quantum-Si (QSI) is forecast to grow earnings by 16.3% and revenue by 68.8% per annum, with EPS expected to increase by 26.2% per annum, despite remaining unprofitable for the next three years. The company recently demonstrated the detection of 19 amino acids in its Proteus development program and reaffirmed earnings guidance for 2026 with an expected revenue of approximately $1.0 million. Quantum-Si is also addressing a Nasdaq non-compliance notice regarding its minimum bid price.

Quantum-Si Presents Interim Proteus Data at World HUPO 2026 Demonstrating a Significant Step Change in Performance Compared to Platinum® Pro

https://investingnews.com/quantum-si-presents-interim-proteus-data-at-world-hupo-2026-demonstrating-a-significant-step-change-in-performance-compared-to-platinum-r-pro/
Quantum-Si Incorporated announced interim development results showing its next-generation Proteus™ platform significantly outperforms its commercially available Platinum® Pro instrument in protein analysis. Proteus demonstrated superior sequencing scale, accuracy, peptide identification, and protein sequence coverage, even though it is still in development. The data, presented at the 2026 World HUPO Congress, indicates Proteus delivers dramatically more data and higher detection rates for amino acids.

Quantum-Si Reports Interim Proteus Platform Data Showing Significant Performance Gains Over Platinum Pro

https://www.quiverquant.com/news/Quantum-Si+Reports+Interim+Proteus+Platform+Data+Showing+Significant+Performance+Gains+Over+Platinum+Pro
Quantum-Si Incorporated announced impressive interim results for its next-generation Proteus platform, demonstrating significant performance gains over its existing Platinum Pro instrument in sequencing scale, accuracy, peptide identification, and protein sequence coverage. The Proteus platform achieved 30 times more alignments in a control peptide study and identified all peptides, detecting 24 proteins compared to Platinum Pro's average of 20.3. CEO Jeff Hawkins highlighted Proteus as a fundamentally advanced technology, with further optimizations expected before its Q2 2027 launch.

Quantum-Si Presents Interim Proteus™ Data at World HUPO 2026 Demonstrating a Significant Step Change in Performance Compared to Platinum® Pro

https://markets.businessinsider.com/news/stocks/quantum-si-presents-interim-proteus-data-at-world-hupo-2026-demonstrating-a-significant-step-change-in-performance-compared-to-platinum-pro-1036579832
Quantum-Si announced interim development results for its next-generation Proteus™ platform, which significantly outperformed its commercially available Platinum® Pro instrument. The data, presented at the 2026 World HUPO Congress, showed Proteus delivered dramatically more data across key measures like sequencing scale, accuracy, and peptide identification, even while still in development. The company projects further improvements for Proteus ahead of its anticipated launch in Q2 2027.

Quantum-Si CEO Jeffrey Hawkins sells $22,610 in stock

https://www.investing.com/news/insider-trading-news/quantumsi-ceo-jeffrey-hawkins-sells-22610-in-stock-93CH-4914350
Quantum-Si CEO Jeffrey Hawkins sold 29,852 shares of Class A Common Stock worth $22,610 in late September 2026 through "sell-to-cover" transactions to meet tax obligations on vested restricted stock units. This insider sale occurred shortly after the company reported second-quarter revenue exceeding expectations but with a 41.8% year-over-year decline and a delay in its next-generation Proteus platform launch to Q2 2027.
Advertisement

To cover taxes on vested stock, Quantum-Si (QSI) officer Jeffrey Alan Hawkins plans to sell 29,852 shares.

https://www.stocktitan.net/sec-filings/QSI/144-quantum-si-inc-sec-filing-9a1bbd0b8a5a.html
Jeffrey Alan Hawkins, an officer and director at Quantum-Si Inc. (QSI), plans to sell 29,852 shares of Class A common stock with an aggregate market value of $22,610.69. This transaction, scheduled for approximately September 21, 2026, is described as a mandatory "sell-to-cover" to satisfy tax withholding obligations from the vesting of 59,609 restricted stock units on September 20, 2026, and is not a discretionary trade.

A Quantum-Si (QSI) officer plans to sell 7,665 shares to cover taxes, not as a discretionary trade.

https://www.stocktitan.net/sec-filings/QSI/144-quantum-si-inc-sec-filing-46d8005c81dd.html
An officer at Quantum-Si Inc. (QSI), Jeffry R. Keyes, has filed a notice to sell 7,665 Class A common shares with an aggregate market value of $5,805.67. This proposed sale is mandated by the issuer to satisfy tax withholding obligations through a "sell-to-cover" transaction related to restricted stock unit vesting, and is explicitly stated not to be a discretionary trade by Keyes. The shares were acquired via restricted stock unit vesting on September 20, 2026, as equity compensation.

A proposed tax sale: Quantum-Si (QSI) officer Christian LaPointe lists 14,516 shares.

https://www.stocktitan.net/sec-filings/QSI/144-quantum-si-inc-sec-filing-42a1203adbf7.html
Christian LaPointe, an officer at Quantum-Si Inc. (QSI), has reported a proposed sale of 14,516 shares of Class A common stock, valued at $10,994.80. This sale is identified as a "sell-to-cover" transaction for tax withholding related to restricted stock unit vesting, rather than a discretionary trade. The filing indicates LaPointe acquired 60,424 shares through vesting on September 20, 2026, with the proposed sale date for the 14,516 shares set for September 21, 2026.

Jonathan M. Rothberg’s Quantum-Si (NASDAQ: QSI) Estate Plan Allows Sale of Up to 8.95M Class A Shares by 2028

https://kalkinemedia.com/us/news/announcements/jonathan-m-rothbergs-quantum-si-nasdaq-qsi-estate-plan-allows-sale-of-up-to-895m-class-a-shares-by-2028
Jonathan M. Rothberg, a significant stakeholder in Quantum-Si (NASDAQ: QSI), has established an estate-planning sales arrangement. This plan permits the sale of up to 8,947,746 Class A shares between January 15, 2027, and January 15, 2028. Rothberg holds a 7.20% stake in Quantum-Si's Class A common stock and fully owns its Class B common stock.

Quantum-Si (NASDAQ: QSI) founder holds all Class B as trusts prep stock sales

https://www.stocktitan.net/sec-filings/QSI/schedule-13d-a-quantum-si-inc-amended-major-shareholder-report-96bc550f70d7.html
Quantum-Si Inc.'s founder, Jonathan M. Rothberg, Ph.D., beneficially owns 7.20% of Class A common stock and 100% of Class B common stock. Trusts for his children have entered into a Rule 10b5-1 trading plan to potentially sell up to 8,947,746 Class A shares between January 15, 2027, and January 15, 2028, for estate planning purposes. These sales are subject to minimum price parameters and are not guaranteed to occur.
Advertisement

Full Transcript: Quantum-Si Q2 2026 Earnings Call

https://www.sahmcapital.com/news/content/full-transcript-quantum-si-q2-2026-earnings-call-2026-08-14
Quantum-Si (NASDAQ: QSI) announced a delay in the Proteus launch to Q2 2027, attributing it to an additional integrated instrument design cycle for improved readiness and reduced manufacturing risk. The company is implementing cost-saving measures, including a 20% workforce reduction, to align expenses with the revised timeline and maintain critical investments. Quantum-Si reiterates its full-year 2026 guidance of approximately $1 million in revenue and adjusted operating expenses of $98 million or less, while exploring opportunities in the non-human proteomics market.

Quantum-Si Reports Second Quarter 2026 Financial Results and Provides Proteus Development Update

https://investingnews.com/quantum-si-reports-second-quarter-2026-financial-results-and-provides-proteus-development-update/
Quantum-Si (Nasdaq: QSI) announced its Q2 2026 financial results, reporting $344 thousand in revenue and a net loss of $23.5 million. The company updated the anticipated launch of its Proteus platform to Q2 2027 to allow for an additional design cycle, and implemented a 20% workforce reduction to extend its cash runway into Q4 2028. Quantum-Si also highlighted an estimated $4 billion market opportunity in non-human proteomics.

BlackRock (QSI holder) discloses 4.6M-share, 2.3% beneficial stake in Quantum-Si Inc

https://www.stocktitan.net/sec-filings/QSI/schedule-13g-a-quantum-si-inc-amended-passive-investment-disclosure-0be0d8ba55cc.html
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 4,598,208 Class A shares in Quantum-Si Inc. This stake represents 2.3% of the class, with BlackRock holding sole voting and dispositive power over these shares. The filing clarifies that while various clients and funds have economic interests, no single person's interest exceeds five percent of Quantum-Si’s outstanding common shares.

Quantum-Si Faces Nasdaq Noncompliance, Delisting Risk Looms

https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3465942/quantum-si-faces-nasdaq-noncompliance-delisting-risk-looms/
Quantum-Si (QSI) has received a Nasdaq noncompliance notice because its Class A common stock traded below $1.00 for 30 consecutive business days. The company has 180 days to regain compliance by maintaining a $1.00 closing bid for 10 consecutive business days, with a possible extension or appeal before delisting. Analysts currently have a Buy rating on QSI with a $4.00 price target, despite the company's weak financial performance and bearish technicals, largely supported by improved Proteus execution and a sufficient cash runway.

Quantum-Si (NASDAQ: QSI) warned on Nasdaq $1.00 bid compliance

https://www.stocktitan.net/sec-filings/QSI/8-k-quantum-si-inc-reports-material-event-f31b262b34e7.html
Quantum-Si Incorporated (NASDAQ: QSI) has received a notice from Nasdaq stating that its Class A common stock no longer meets the minimum $1.00 bid price requirement, having traded below this level for 30 consecutive business days. The company has an initial 180-calendar-day period, until January 19, 2027, to regain compliance by having its stock close at or above $1.00 for at least 10 consecutive business days. Failure to comply could lead to potential delisting, though options like transferring to The Nasdaq Capital Market or implementing a reverse stock split are available.
Advertisement

Branford-based biotech Quantum-Si at risk of Nasdaq delisting, again

https://hartfordbusiness.com/article/branford-based-biotech-quantum-si-at-risk-of-nasdaq-delisting-again/
Branford-based biotech firm Quantum-Si is once again at risk of being delisted from Nasdaq after its stock fell below the minimum $1 per share requirement for 30 consecutive business days. This marks the second time in less than two years the company has received such a warning. Quantum-Si, which commercializes protein-sequencing technology, has until January 19, 2027, to regain compliance.

Shareholders Can't Ignore US$614k Of Sales By Quantum-Si Insiders

https://www.sahmcapital.com/news/content/shareholders-cant-ignore-us614k-of-sales-by-quantum-si-insiders-2026-07-02
Insiders at Quantum-Si Incorporated sold US$614k worth of stock over the past year, primarily at a higher price than the current market value, suggesting they may have avoided further losses. Despite some insider buying earlier, recent insider selling of US$314k in the last three months, with no corresponding purchases, indicates potential concerns about the stock's valuation. While insiders still own 17% of the company, this selling activity warrants caution for potential investors.

Quantum-Si (QSI) CEO Jeffrey Hawkins reports $20,996 stock sale

https://www.investing.com/news/insider-trading-news/quantumsi-qsi-ceo-jeffrey-hawkins-reports-20996-stock-sale-93CH-4759482
Quantum-Si (QSI) CEO Jeffrey Hawkins sold $20,996 worth of company stock across two transactions in late June to cover taxes related to vesting restricted stock units. Despite the sale, which occurred at prices between $0.88 and $1.005, Hawkins still directly holds over 3.6 million shares. The stock has seen a 59% decline over the past year, though InvestingPro analysis suggests it may be undervalued.

Quantum-Si Incorporated Class A Actuals & Estimates (NASDAQ:QSI)

https://www.tradingview.com/symbols/NASDAQ-QSI/forecast-actuals-and-estimates/?category=cash_flow
This article provides an overview of Quantum-Si Incorporated (NASDAQ: QSI) stock performance, financial actuals, and analyst estimates. It covers stock price movements, historical highs and lows, market capitalization, earnings reports, and future forecasts, along with general company information like dividends and employee numbers.

Quantum-Si (QSI) CEO Jeffrey Hawkins reports $20,996 stock sale By Investing.com

https://m.au.investing.com/news/stock-market-news/quantumsi-qsi-ceo-jeffrey-hawkins-reports-20996-stock-sale-93CH-4503629?ampMode=1
Jeffrey Alan Hawkins, CEO of Quantum-Si Inc. (NASDAQ:QSI), sold $20,996 worth of company stock in late June across two transactions. These sales were made to cover taxes related to the vesting of restricted stock units. Despite an overall stock decline, Quantum-Si reported strong Q1 2026 earnings, exceeding revenue and EPS forecasts, and is focusing on expanding its Proteus platform through new partnerships and roadshows.
Advertisement

Quantum-Si CPO John Vieceli sells $28,052 in stock

https://m.uk.investing.com/news/stock-market-news/quantumsi-cpo-john-vieceli-sells-28052-in-stock-93CH-4743493?ampMode=1
Quantum-Si's CPO, John Vieceli, sold 30,223 shares of Class A Common Stock for a total of $28,052 across two transactions on June 22 and June 23, 2026. These sales were mandatory to cover withholding taxes for vested restricted stock units. Vieceli still directly owns 1,140,434 shares after these transactions.

Quantum-Si (QSI) CFO offloads 8,233 shares in mandatory tax sell-to-cover

https://www.stocktitan.net/sec-filings/QSI/form-4-quantum-si-inc-insider-trading-activity-e53d828a53b5.html
Quantum-Si Inc.'s CFO, Jeffry R. Keyes, sold a total of 8,233 Class A Common Stock shares on June 22nd and 23rd, 2026. These transactions were mandatory "sell-to-cover" sales to meet tax obligations on vested restricted stock units, not discretionary trades. Following these sales, Keyes directly holds 1,724,349 shares of Quantum-Si Class A Common Stock.

Quantum-Si (QSI) CEO Jeffrey Hawkins reports $20,996 stock sale

https://m.uk.investing.com/news/stock-market-news/quantumsi-qsi-ceo-jeffrey-hawkins-reports-20996-stock-sale-93CH-4743485?ampMode=1
Quantum-Si (QSI) CEO Jeffrey Hawkins sold company stock totaling $20,996 in late June to cover withholding taxes on restricted stock units. Despite the sales, Hawkins still directly holds over 3.6 million shares. The stock has seen a significant decline, falling 59% in the past year, while the company recently reported exceeding Q1 2026 earnings and revenue expectations, and announced a partnership to enhance its protein sequencing platform.

Quantum-Si GC LaPointe sells $14,468 in company shares

https://m.uk.investing.com/news/stock-market-news/quantumsi-gc-lapointe-sells-14468-in-company-shares-93CH-4743499?ampMode=1
Christian LaPointe, General Counsel of Quantum-Si Inc. (NASDAQ:QSI), sold $14,468 worth of Class A Common Stock across two transactions on June 22 and June 23, 2026. The sales were mandatory "sell-to-cover" provisions for tax withholding due to restricted stock unit vesting. Despite recent stock volatility and a 59% drop over the past year, InvestingPro analysis suggests the stock may be undervalued, and the company recently reported exceeding Q1 2026 earnings expectations and announced a partnership with Cell Signaling Technology.

Quantum-Si (QSI) CEO executes mandatory sell-to-cover on 22,621 vested shares

https://www.stocktitan.net/sec-filings/QSI/form-4-quantum-si-inc-insider-trading-activity-ba599456a5ff.html
Quantum-Si Inc.'s President & CEO, Jeffrey Alan Hawkins, executed a mandatory sell-to-cover of 22,621 Class A Common Stock shares to satisfy tax withholding obligations on vested restricted stock units. The sales occurred on June 22 and June 23, 2026, at weighted average prices of $0.9574 and $0.8990 per share, respectively. Following these transactions, Hawkins directly holds 3,669,802 shares.
Advertisement

Form 144 Quantum-Si Inc For: 24 June By Investing.com

https://uk.investing.com/news/stock-market-news/form-144-quantumsi-inc-for-24-june-93CH-4743541
The article reports that Quantum-Si Inc. filed Form 144 for June 24, as published by Investing.com. This filing is a notice indicating the intent to sell restricted securities without being registered with the SEC. The article lists relevant financial market data, including various indices, commodities, and stock performances, specific to June 25, 2026.

Form 144 Quantum-Si Inc For: 24 June By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-quantumsi-inc-for-24-june-93CH-4706570
This article announces the filing of Form 144 for Quantum-Si Inc. on June 24, as reported by Investing.com. It is a brief, technical notification regarding a financial filing for the company.

Quantum-Si CPO John Vieceli sells $28,052 in stock By Investing.com

https://m.za.investing.com/news/stock-market-news/quantumsi-cpo-john-vieceli-sells-28052-in-stock-93CH-4343039?ampMode=1
John Vieceli, CPO of Quantum-Si Inc (NASDAQ:QSI), sold 30,223 shares of Class A Common Stock for $28,052 in transactions on June 22 and June 23, 2026. These sales were mandatory "sell-to-cover" provisions to satisfy withholding taxes on vested restricted stock units. Vieceli now directly owns 1,140,434 shares; the stock has seen significant volatility and is down 59% over the past year.

Quantum‑Si (NASDAQ: QSI) plans sale of 79,589 RSU shares via Morgan Stanley

https://www.stocktitan.net/sec-filings/QSI/144-quantum-si-inc-sec-filing-7fc7cd55081c.html
Quantum-Si Incorporated (NASDAQ: QSI) has filed a Form 144 to report the intended sale of 79,589 shares of Class A Common Stock. These shares are related to restricted stock unit vesting on June 20, 2026, and represent equity compensation for services rendered. Morgan Stanley Smith Barney LLC is named as the broker for this transaction.

Quantum-Si (QSI) CPO sells 30,223 shares to cover RSU tax withholding

https://www.stocktitan.net/sec-filings/QSI/form-4-quantum-si-inc-insider-trading-activity-d64fb557930f.html
Quantum-Si Inc.'s Chief Product Officer, John S. Vieceli, sold 30,223 shares of Class A Common Stock across two transactions on June 22nd and 23rd, 2026. These sales were mandated by a "sell-to-cover" provision to handle tax obligations from vested restricted stock units, occurring at weighted average prices of $0.9574 and $0.899 per share. Following these transactions, Vieceli still retains a significant holding of 1,140,434 shares in the company.
Advertisement

Quantum-Si (NASDAQ: QSI) files sale notice for 21,676 Class A shares

https://www.stocktitan.net/sec-filings/QSI/144-quantum-si-inc-sec-filing-dc42e4ddefdf.html
Quantum-Si (NASDAQ: QSI) has filed a Form 144 notice for the proposed sale of 21,676 Class A common shares, linked to the vesting of Restricted Stock Units on June 20, 2026. The filing also disclosed a prior sale of 74,763 shares by Jeffry Keyes on April 20, 2026. This notice indicates potential insider selling and an upcoming increase in shares available to the market.

Affiliate files sale notice for Quantum‑Si (NASDAQ: QSI)

https://www.stocktitan.net/sec-filings/QSI/144-quantum-si-inc-sec-filing-2216608e6143.html
An affiliate of Quantum-Si (NASDAQ: QSI) has filed a Form 144, indicating proposed sales of Class A common stock. The filing details a Restricted Stock Unit (RSU) vesting of 59,609 shares on June 20, 2026, as equity compensation and reports a prior sale of 167,424 shares by Jeffrey Hawkins on April 20, 2026. This SEC filing serves as a standard insider notice of sale by an affiliate and outlines the securities information and recent transactions.

Quantum‑Si (NASDAQ: QSI) Form 144: 60,425 RSUs vest, resale listed

https://www.stocktitan.net/sec-filings/QSI/144-quantum-si-inc-sec-filing-c73930e19b18.html
Quantum-Si Incorporated (NASDAQ: QSI) filed a Form 144 to report a proposed sale of 60,425 shares of Class A Common Stock. This sale is a result of Restricted Stock Unit (RSU) vesting on June 20, 2026, and will be facilitated by Morgan Stanley Smith Barney LLC. The filing indicates a routine equity compensation event, with the actual sale depending on holder decisions and market conditions.

Quantum-Si CPO John Vieceli sells $28,052 in stock

https://www.investing.com/news/insider-trading-news/quantumsi-cpo-john-vieceli-sells-28052-in-stock-93CH-4759495
John Vieceli, Chief Product Officer at Quantum-Si Inc. (NASDAQ:QSI), sold 30,223 shares of Class A Common Stock for a total of $28,052 over two transactions on June 22 and June 23, 2026. These sales were mandated by a sell-to-cover provision for withholding taxes on vested restricted stock units. Despite the stock's 59% drop over the past year, InvestingPro analysis suggests the company is currently undervalued, though it faces negative free cash flow.

Quantum-Si (QSI) Form 25: Nasdaq withdrawal of warrants listing

https://www.stocktitan.net/sec-filings/QSI/25-nse-quantum-si-inc-sec-filing-8835db95f44b.html
Quantum-Si Inc. (QSI) has filed a Form 25 with the SEC, notifying Nasdaq of the voluntary withdrawal of its warrant class from listing and registration. This action, certified by Nasdaq as compliant with exchange procedures, means less visibility and potentially lower trading volume for the warrants. The filing details the regulatory rules governing such withdrawals and provides key information about the issuer.
Advertisement

Quantum-Si and Cell Signaling Technology Partner to Advance Post-Translational Modification Analysis on Proteus™

https://www.stocktitan.net/news/QSI/quantum-si-and-cell-signaling-technology-partner-to-advance-post-vx5xlx8trbjn.html
Quantum-Si (QSI) has announced a partnership with Cell Signaling Technology (CST) to further the analysis of post-translational modifications (PTM) using Quantum-Si's Proteus™ single-molecule protein sequencing platform. The collaboration aims to integrate CST's expertise in PTM detection and enrichment with Quantum-Si's technology to enable site-resolved detection and quantification of proteins and PTMs for research applications. This partnership is expected to accelerate the validation of Proteus™ PTM capabilities and support new methods for interrogating complex biological systems.

Quantum-Si and Cell Signaling Technology Partner to Advance Post-Translational Modification Analysis on Proteus™

https://finance.yahoo.com/sectors/healthcare/articles/quantum-si-cell-signaling-technology-120000622.html
Quantum-Si and Cell Signaling Technology (CST) have announced a partnership to advance and validate post-translational modification (PTM) analysis on Quantum-Si's Proteus™ single-molecule protein sequencing platform. The collaboration will integrate CST's expertise in PTM detection and enrichment with Quantum-Si's technology to enable site-resolved detection and quantification of proteins and PTMs. This partnership aims to accelerate the validation of Proteus's PTM capabilities and support new ways of interrogating complex biological systems for research applications.

Quantum-Si and Cell Signaling Technology Partner to Advance Post-Translational Modification Analysis on Proteus

https://www.biospace.com/press-releases/quantum-si-and-cell-signaling-technology-partner-to-advance-post-translational-modification-analysis-on-proteus
Quantum-Si and Cell Signaling Technology (CST) have announced a partnership to advance post-translational modification (PTM) analysis on Quantum-Si's Proteus single-molecule protein sequencing platform. This collaboration will integrate CST's expertise in PTM detection and immunoaffinity enrichment with Quantum-Si's workflows to enable site-resolved detection and quantitation of proteins and PTMs for research applications. The partnership aims to validate Proteus's PTM capabilities by using CST's datasets to refine Quantum-Si's analysis methods and comparing results with orthogonal mass spectrometry data.

Quantum-Si Announces the Expansion of the Proteus Roadshow

https://investingnews.com/quantum-si-announces-the-expansion-of-the-proteus-roadshow/
Quantum-Si Incorporated announced the expansion of its Proteus roadshow, aimed at educating the market about its Proteus platform for single-molecule protein sequencing. The roadshow has already visited cities in the US and Europe and is scheduled to stop in North Carolina's Research Triangle Park, St. Louis, and Italy in June, in preparation for the Proteus platform's commercial launch. This initiative seeks to increase customer awareness of their proprietary technology.

[Form 4] Quantum-Si Inc Insider Trading Activity

https://www.stocktitan.net/sec-filings/QSI/form-4-quantum-si-inc-insider-trading-activity-2646fc179a18.html
Quantum-Si Inc director Amir Jafri has reported a new stock option grant, receiving the right to purchase 251,185 shares of Class A Common Stock at an exercise price of $0.8539 per share. The options will vest at the company's next annual stockholders meeting, provided continuous service. Following this transaction, Jafri directly holds 115,942 shares of Class A Common Stock.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement